在与运动和认知严重程度相关的亚组中,对帕金森病患者的多奥米克剖析
Efi Athieniti1, Sotiroula Afxenti1, George Minadakis1
1The Cyprus Institute of Neurology and Genetics, Iroon Avenue 6, Nicosia, 2371, Cyprus.
Neurobiology of disease
|February 4, 2026
概括
帕金森病 (PD) 的严重程度差异很大,影响临床试验. 多omics分析确定了与运动和认知衰退相关的分子因素,有助于理解PD进展,并使精准医学成为可能.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 蛋白质组学是指蛋白质组学.
背景情况:
- 帕金森病 (PD) 在临床严重程度上表现出显著的异质性,使临床试验解释复杂化.
- 了解PD进展的分子基础对于开发有效的治疗方法和生物标志物至关重要.
研究的目的:
- 通过使用多omics数据,识别与帕金森病中运动和认知严重程度相关的分子因素.
- 根据与疾病严重程度相关的分子概况,将PD患者分为分组.
- 阐明驱动PD运动和认知衰退的生物机制.
主要方法:
- 多奥米克因子分析 (MOFA) 应用于来自帕金森氏症进展标志物倡议 (PPMI) 队列的全血RNA,miRNA,脑脊液 (CSF) 和血蛋白质组学数据.
- 分子因素与运动 (MDS-UPDRS3) 和认知 (语义流性测试,SFT) 功能相关,调整为共变量.
- 根据确定的分子因素定义了患者子组,以分析不同的临床严重性概况.
主要成果:
- 三个分子因素与运动严重程度 (MDS-UPDRS3) 显著相关,两个与认知功能 (SFT) 相关,独立于年龄,性别和药物.
- 分层揭示了严重的运动和认知障碍的独特分子特征.
- 严重的运动群显示出细胞毒性自然杀手细胞机制的放松调节,以及与内质网膜和密集核心囊泡相关的CSF蛋白质的改变.
- 严重的认知集群表现出补充系统和突触功能障碍的变化.
结论:
- 多omics数据集成为了解帕金森病的运动和认知衰退背后的分子机制提供了洞察力.
- 已识别的分子因素和相关的生物学途径可以作为疾病严重程度的潜在生物标志物.
- 这种方法支持开发用于帕金森病的精准医学策略.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.4K
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
2.0K
相关概念视频
Neural Regulation
34.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
34.8K
Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Parkinson Disease l: Introduction
28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
Parkinson Disease ll: Pathophysiology
28
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
28
